Maze, Richard Scheller
Richard Scheller is leaving 23andMe personal genomics company, where he served for four years as the CSO and head of therapeutics.
The executive will become a member of Maze Therapeutics’ board of directors, while he was also appointed as chairman of R&D at Bridge Bio.
Maze CEO, Jason Coloma, commented that Scheller is entering the company with a “distinguished academic career and accomplishments as a drug discovery and development leader.”
On his side, Scheller stated that he is impressed by the science behind Maze, which “brings together a wealth of human genetics insights and an unparalleled knowledge of genomics.”
Prior to his position at 23andMe, Scheller spent 14 years at Genentech, where he was the EVP of research and early development.
Scheller will remain a board member of 23andMe.